Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis | Allergy and Clinical Immunology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe AsthmaA Systematic Review and Meta-analysis

Educational Objective
To review therapeutic strategies for patients with persistent uncontrolled asthma.
1 Credit CME
Key Points

Question  Is adding a long-acting muscarinic antagonist (LAMA) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) associated with differences in clinical outcomes and adverse events among individuals with moderate to severe persistent asthma?

Findings  In this systematic review and meta-analysis that included 20 randomized clinical trials and 11 894 patients, triple therapy (ICS, LABA, and LAMA), compared with dual therapy (ICS plus LABA), was significantly associated with fewer severe asthma exacerbations (risk ratio, 0.83) and slightly better asthma control, but no significant difference in quality of life or most adverse events.

Meaning  Among patients with moderate to severe asthma, triple therapy compared with dual therapy was significantly associated with fewer severe asthma exacerbations and modest improvements in asthma control but no significant difference in quality of life.

Abstract

Importance  The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear.

Objective  To systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma.

Data Sources  MEDLINE, Embase, CENTRAL, ICTRP, FDA, and EMA databases from November 2017, to December 8, 2020, without language restriction.

Study Selection  Two investigators independently selected randomized clinical trials (RCTs) comparing triple vs dual therapy in patients with moderate to severe asthma.

Data Extraction and Synthesis  Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses, including individual patient-level exacerbation data, were used. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence.

Main Outcomes and Measures  Severe exacerbations, asthma control (measured using the Asthma Control Questionnaire [ACQ-7], a 7-item list with each item ranging from 0 [totally controlled] to 6 [severely uncontrolled]; minimal important difference, 0.5), quality of life (measured using the Asthma-related Quality of Life [AQLQ] tool; score range, 1 [severely impaired] to 7 [no impairment]; minimal important difference, 0.5), mortality, and adverse events.

Results  Twenty RCTs using 3 LAMA types that enrolled 11 894 children and adults (mean age, 52 years [range, 9-71 years]; 57.7% female) were included. High-certainty evidence showed that triple therapy vs dual therapy was significantly associated with a reduction in severe exacerbation risk (9 trials [9932 patients]; 22.7% vs 27.4%; risk ratio, 0.83 [95% CI, 0.77 to 0.90]) and an improvement in asthma control (14 trials [11 230 patients]; standardized mean difference [SMD], −0.06 [95% CI, −0.10 to −0.02]; mean difference in ACQ-7 scale, −0.04 [95% CI, −0.07 to −0.01]). There were no significant differences in asthma-related quality of life (7 trials [5247 patients]; SMD, 0.05 [95% CI, −0.03 to 0.13]; mean difference in AQLQ score, 0.05 [95% CI, −0.03 to 0.13]; moderate-certainty evidence) or mortality (17 trials [11 595 patients]; 0.12% vs 0.12%; risk ratio, 0.96 [95% CI, 0.33 to 2.75]; high-certainty evidence) between dual and triple therapy. Triple therapy was significantly associated with increased dry mouth and dysphonia (10 trials [7395 patients]; 3.0% vs 1.8%; risk ratio, 1.65 [95% CI, 1.14 to 2.38]; high-certainty evidence), but treatment-related and serious adverse events were not significantly different between groups (moderate-certainty evidence).

Conclusions and Relevance  Among children (aged 6 to 18 years) and adults with moderate to severe asthma, triple therapy, compared with dual therapy, was significantly associated with fewer severe asthma exacerbations and modest improvements in asthma control without significant differences in quality of life or mortality.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Derek K. Chu, MD, PhD, Division of Clinical Immunology and Allergy, Department of Medicine and Department of Health Research Methods, Evidence, and Impact, McMaster University Medical Centre, 1280 Main St W, Room 3V41, Hamilton, ON L8S 4K1, Canada (chudk@mcmaster.ca).

Accepted for Publication: April 30, 2021.

Published Online: May 19, 2021. doi:10.1001/jama.2021.7872

Author Contributions: Drs Kim and Chu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Kim, Saleh, Whalen-Browne, Chu.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: Kim, Saleh, Whalen-Browne, Chu.

Statistical analysis: Kim, Chu.

Administrative, technical, or material support: Kim, Whalen-Browne, Chu.

Supervision: Chu.

Conflict of Interest Disclosures: Dr O'Byrne reported receipt of grants from AstraZeneca, GlaxoSmithKline (GSK), Medimmune, Genentech, Bayer, Merck, and Novartis; and personal fees from AstraZeneca, GSK, Covis, Teva, Sage, and Chiesi, during the conduct of the study. Dr Chu reported receipt of the CAAIF-AllerGen NCE-CSACI Emerging Clinician Scientist Award (Canadian Allergy, Asthma and Immunology Foundation [CAAIF]-AllerGen NCE [Allergy, Genes and Environment Network]-Canadian Society of Allergy and Clinical Immunology [CSACI]), all of which are nonprofits or federally funded (Canadian Institutes of Health Research). No other disclosures were reported.

Meeting Presentation: Presented at the American Thoracic Society 2021 international conference (virtual meeting); May 19, 2021.

References
1.
Global Initiative for Asthma.  Global Strategy for Asthma Management and Prevention.  2020 update. Accessed December 16, 2020. https://ginasthma.org
2.
Suruki  RY , Daugherty  JB , Boudiaf  N , Albers  FC .  The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.   BMC Pulm Med. 2017;17(1):74. doi:10.1186/s12890-017-0409-3PubMedGoogle ScholarCrossref
3.
Buhl  R , Heaney  LG , Loefroth  E ,  et al.  One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings.   Respir Med. 2020;162:105859. doi:10.1016/j.rmed.2019.105859PubMedGoogle Scholar
4.
Cloutier  MM , Baptist  AP , Blake  KV ,  et al; Expert Panel Working Group of the National Heart, Lung, and Blood Institute.  2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.   J Allergy Clin Immunol. 2020;146(6):1217-1270. doi:10.1016/j.jaci.2020.10.003PubMedGoogle ScholarCrossref
5.
Cloutier  MM , Dixon  AE , Krishnan  JA , Lemanske  RF  Jr , Pace  W , Schatz  M .  Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program.   JAMA. 2020;324(22):2301-2317. doi:10.1001/jama.2020.21974PubMedGoogle ScholarCrossref
6.
Buels  KS , Fryer  AD .  Muscarinic receptor antagonists: effects on pulmonary function.   Handb Exp Pharmacol. 2012;(208):317-341. doi:10.1007/978-3-642-23274-9_14PubMedGoogle Scholar
7.
Lefebvre  P , Duh  MS , Lafeuille  M-H ,  et al.  Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.   J Allergy Clin Immunol. 2015;136(6):1488-1495. doi:10.1016/j.jaci.2015.07.046PubMedGoogle ScholarCrossref
8.
Waljee  AK , Rogers  MAM , Lin  P ,  et al.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.   BMJ. 2017;357:j1415. doi:10.1136/bmj.j1415PubMedGoogle ScholarCrossref
9.
Canonica  GW , Colombo  GL , Bruno  GM ,  et al; SANI Network.  Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry.   World Allergy Organ J. 2019;12(1):100007. doi:10.1016/j.waojou.2018.12.001PubMedGoogle Scholar
10.
Anderson  WC  III , Szefler  SJ .  Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?   Ann Allergy Asthma Immunol. 2019;122(4):367-372. doi:10.1016/j.anai.2019.01.018PubMedGoogle ScholarCrossref
11.
National Heart, Lung, and Blood Institute.  Needs assessment report for potential update of the Expert Panel Report-3(2007): guidelines for the diagnosis and management of asthma, April 2014. Accessed December 16, 2020. https://www.nhlbi.nih.gov/sites/default/files/media/docs/NHLBAC-Asthma-WG-Report-2-2015.pdf
12.
Sobieraj  DM , Baker  WL , Nguyen  E ,  et al.  Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis.   JAMA. 2018;319(14):1473-1484. doi:10.1001/jama.2018.2757PubMedGoogle ScholarCrossref
13.
Kew  KM , Dahri  K .  Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.   Cochrane Database Syst Rev. 2016;(1):CD011721. doi:10.1002/14651858.CD011721.pub2PubMedGoogle Scholar
14.
Rodrigo  GJ , Neffen  H .  Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: a systematic review.   Pediatr Allergy Immunol. 2017;28(6):573-578. doi:10.1111/pai.12759PubMedGoogle ScholarCrossref
15.
Higgins  J , Thomas  J , eds  et al.  Cochrane Handbook for Systematic Reviews of Interventions Version 6.2, 2021. Accessed April, 25, 2021. http://www.training.cochrane.org/handbook
16.
Guyatt  GH , Oxman  AD , Vist  GE ,  et al; GRADE Working Group.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.   BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.ADPubMedGoogle ScholarCrossref
17.
Moher  D , Liberati  A , Tetzlaff  J , Altman  DG ; PRISMA Group.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.   PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097PubMedGoogle Scholar
18.
Juniper  EF , O’Byrne  PM , Guyatt  GH , Ferrie  PJ , King  DR .  Development and validation of a questionnaire to measure asthma control.   Eur Respir J. 1999;14(4):902-907. doi:10.1034/j.1399-3003.1999.14d29.xPubMedGoogle ScholarCrossref
19.
Nathan  RA , Sorkness  CA , Kosinski  M ,  et al.  Development of the asthma control test: a survey for assessing asthma control.   J Allergy Clin Immunol. 2004;113(1):59-65. doi:10.1016/j.jaci.2003.09.008PubMedGoogle ScholarCrossref
20.
Juniper  EF , Guyatt  GH , Epstein  RS , Ferrie  PJ , Jaeschke  R , Hiller  TK .  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.   Thorax. 1992;47(2):76-83. doi:10.1136/thx.47.2.76PubMedGoogle ScholarCrossref
21.
Juniper  EF , Guyatt  GH , Cox  FM , Ferrie  PJ , King  DR .  Development and validation of the Mini Asthma Quality of Life Questionnaire.   Eur Respir J. 1999;14(1):32-38. doi:10.1034/j.1399-3003.1999.14a08.xPubMedGoogle ScholarCrossref
22.
Reddel  HK , Taylor  DR , Bateman  ED ,  et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.   Am J Respir Crit Care Med. 2009;180(1):59-99. doi:10.1164/rccm.200801-060STPubMedGoogle ScholarCrossref
23.
Juniper  EF , Svensson  K , Mörk  A-C , Ståhl  E .  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire.   Respir Med. 2005;99(5):553-558. doi:10.1016/j.rmed.2004.10.008PubMedGoogle ScholarCrossref
24.
Juniper  EF , Buist  AS , Cox  FM , Ferrie  PJ , King  DR .  Validation of a standardized version of the Asthma Quality of Life Questionnaire.   Chest. 1999;115(5):1265-1270. doi:10.1378/chest.115.5.1265PubMedGoogle ScholarCrossref
25.
Santanello  NC , Zhang  J , Seidenberg  B , Reiss  TF , Barber  BL .  What are minimal important changes for asthma measures in a clinical trial?   Eur Respir J. 1999;14(1):23-27. doi:10.1034/j.1399-3003.1999.14a06.xPubMedGoogle ScholarCrossref
26.
Tepper  RS , Wise  RS , Covar  R ,  et al.  Asthma outcomes: pulmonary physiology.   J Allergy Clin Immunol. 2012;129(3)(suppl):S65-S87. doi:10.1016/j.jaci.2011.12.986PubMedGoogle ScholarCrossref
27.
Sterne  JAC , Savović  J , Page  MJ ,  et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials.   BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898PubMedGoogle ScholarCrossref
28.
Akl  EA , Sun  X , Busse  JW ,  et al.  Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid.   J Clin Epidemiol. 2012;65(3):262-267. doi:10.1016/j.jclinepi.2011.04.015PubMedGoogle ScholarCrossref
29.
Dechartres  A , Altman  DG , Trinquart  L , Boutron  I , Ravaud  P .  Association between analytic strategy and estimates of treatment outcomes in meta-analyses.   JAMA. 2014;312(6):623-630. doi:10.1001/jama.2014.8166PubMedGoogle ScholarCrossref
30.
Guyatt  GH , Oxman  AD , Vist  G ,  et al.  GRADE guidelines: 4. rating the quality of evidence—study limitations (risk of bias).   J Clin Epidemiol. 2011;64(4):407-415. doi:10.1016/j.jclinepi.2010.07.017PubMedGoogle ScholarCrossref
31.
Lan  KKG , DeMets  DL .  Discrete sequential boundaries for clinical trials.   Biometrika. 1983;70(3):659-663. doi:10.2307/2336502Google ScholarCrossref
32.
Thorlund  K , Walter  SD , Johnston  BC , Furukawa  TA , Guyatt  GH .  Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability.   Res Synth Methods. 2011;2(3):188-203. doi:10.1002/jrsm.46PubMedGoogle ScholarCrossref
33.
Guyatt  GH , Thorlund  K , Oxman  AD ,  et al.  GRADE guidelines: 13. preparing summary of findings tables and evidence profiles-continuous outcomes.   J Clin Epidemiol. 2013;66(2):173-183. doi:10.1016/j.jclinepi.2012.08.001PubMedGoogle ScholarCrossref
34.
Guyatt  GH , Oxman  AD , Kunz  R ,  et al; GRADE Working Group.  GRADE guidelines: 7. rating the quality of evidence—inconsistency.   J Clin Epidemiol. 2011;64(12):1294-1302. doi:10.1016/j.jclinepi.2011.03.017PubMedGoogle ScholarCrossref
35.
Akl  EA , Johnston  BC , Alonso-Coello  P ,  et al.  Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers.   PLoS One. 2013;8(2):e57132. doi:10.1371/journal.pone.0057132PubMedGoogle Scholar
36.
Guyatt  GH , Oxman  AD , Montori  V ,  et al.  GRADE guidelines: 5. rating the quality of evidence—publication bias.   J Clin Epidemiol. 2011;64(12):1277-1282. doi:10.1016/j.jclinepi.2011.01.011PubMedGoogle ScholarCrossref
37.
Guyatt  G , Oxman  AD , Akl  EA ,  et al.  GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables.   J Clin Epidemiol. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026PubMedGoogle ScholarCrossref
38.
Schandelmaier  S , Briel  M , Varadhan  R ,  et al.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.   CMAJ. 2020;192(32):E901-E906. doi:10.1503/cmaj.200077PubMedGoogle ScholarCrossref
39.
Guyot  P , Ades  AE , Ouwens  MJNM , Welton  NJ .  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.   BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9PubMedGoogle ScholarCrossref
40.
Wei  Y , Royston  P .  Reconstructing time-to-event data from published Kaplan-Meier curves.   Stata J. 2017;17(4):786-802. doi:10.1177/1536867X1801700402PubMedGoogle ScholarCrossref
41.
Wasserstein  RL , Lazar  NA .  The ASA statement on p values: context, process, and purpose.   Am Stat. 2016;70(2):129-133. doi:10.1080/00031305.2016.1154108Google ScholarCrossref
42.
Santesso  N , Glenton  C , Dahm  P ,  et al; GRADE Working Group.  GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions.   J Clin Epidemiol. 2020;119:126-135. doi:10.1016/j.jclinepi.2019.10.014PubMedGoogle ScholarCrossref
43.
Virchow  JC , Kuna  P , Paggiaro  P ,  et al.  Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.   Lancet. 2019;394(10210):1737-1749. doi:10.1016/S0140-6736(19)32215-9PubMedGoogle ScholarCrossref
44.
Kerstjens  HAM , Engel  M , Dahl  R ,  et al.  Tiotropium in asthma poorly controlled with standard combination therapy.   N Engl J Med. 2012;367(13):1198-1207. doi:10.1056/NEJMoa1208606PubMedGoogle ScholarCrossref
45.
Yoshida  M , Nakano  T , Fukuyama  S ,  et al.  Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes.   Pulm Pharmacol Ther. 2013;26(2):159-166. doi:10.1016/j.pupt.2012.09.007PubMedGoogle ScholarCrossref
46.
Yoshida  M , Kaneko  Y , Ishimatsu  A , Komori  M , Iwanaga  T , Inoue  H .  Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma.   Pulm Pharmacol Ther. 2017;42:7-12. doi:10.1016/j.pupt.2016.11.004PubMedGoogle ScholarCrossref
47.
Jabbal  S , Manoharan  A , Lipworth  BJ .  Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma.   Clin Exp Allergy. 2017;47(10):1239-1245. doi:10.1111/cea.12972PubMedGoogle ScholarCrossref
48.
Kerstjens  HAM , Disse  B , Schröder-Babo  W ,  et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.   J Allergy Clin Immunol. 2011;128(2):308-314. doi:10.1016/j.jaci.2011.04.039PubMedGoogle ScholarCrossref
49.
Szefler  SJ , Murphy  K , Harper  T  III ,  et al.  A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.   J Allergy Clin Immunol. 2017;140(5):1277-1287. doi:10.1016/j.jaci.2017.01.014PubMedGoogle ScholarCrossref
50.
Hamelmann  E , Bernstein  JA , Vandewalker  M ,  et al.  A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.   Eur Respir J. 2017;49(1):1601100. doi:10.1183/13993003.01100-2016PubMedGoogle Scholar
51.
Hoshino  M , Akitsu  K , Ohtawa  J .  Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β2-agonist in for patients with asthma.   J Asthma. 2019;56(9):995-1003. doi:10.1080/02770903.2018.1514047 PubMedGoogle ScholarCrossref
52.
Ishiura  Y , Fujimura  M , Ohkura  N ,  et al.  Effect of triple therapy in patients with asthma-COPD overlap.   Int J Clin Pharmacol Ther. 2019;57(8):384-392. doi:10.5414/CP203382PubMedGoogle ScholarCrossref
53.
Ishiura  Y , Fujimura  M , Ohkura  N ,  et al.  Triple therapy with budesonide/glycopyrrolate/ formoterol fumarate improves inspiratory capacity in patients with asthma-chronic obstructive pulmonary disease overlap.   Int J Chron Obstruct Pulmon Dis. 2020;15:269-277. doi:10.2147/COPD.S231004PubMedGoogle ScholarCrossref
54.
Jabbal  S , Kuo  CRW , Lipworth  B .  Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics.   Clin Exp Allergy. 2020;50(10):1140-1147. doi:10.1111/cea.13702PubMedGoogle ScholarCrossref
55.
Chiesi Farmaceutici.  A multicentre, randomised, double-blind, active-controlled, 3-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of CHF 5259 (glycopyrrolate) plus Foster 100/6µg (fixed combination of beclomethasone dipropionate plus formoterol) in a metered dose inhaler for the treatment of patients with uncontrolled asthma under medium doses of inhaled corticosteroids plus long-acting β2-agonists. EudraCT number: 2013-003043-36. Accessed December 16, 2020. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003043-36/results
56.
Watz  H , Hohlfeld  JM , Singh  D ,  et al  Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.   Respir Res. 2020;21(1):87. doi:10.1186/s12931-020-01349-5PubMedGoogle ScholarCrossref
57.
Kerstjens  HAM , Maspero  J , Chapman  KR ,  et al; IRIDIUM Trial Investigators.  Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.   Lancet Respir Med. 2020;8(10):1000-1012. doi:10.1016/S2213-2600(20)30190-9PubMedGoogle ScholarCrossref
58.
Lee  LA , Bailes  Z , Barnes  N ,  et al.  Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.   Lancet Respir Med. 2021;9(1):69-84. doi:10.1016/s2213600(20)30389-1PubMedGoogle ScholarCrossref
59.
Pearl Therapeutics  Efficacy and safety of PT001 to placebo and open-label Spiriva Respimat in subjects with persistant asthma. August 12, 2020. Accessed December, 16, 2020. https://clinicaltrials.gov/ct2/show/results/NCT03358147
60.
Ohta  K , Ichinose  M , Tohda  Y ,  et al.  Long-term once-daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study.   PLoS One. 2015;10(4):e0124109. doi:10.1371/journal.pone.0124109PubMedGoogle Scholar
61.
Wang  K , Tian  P , Fan  Y , Wang  Y , Liu  C .  Assessment of second-line treatments for patients with uncontrolled moderate asthma.   Int J Clin Exp Med. 2015;8(10):19476-19480.PubMedGoogle Scholar
62.
Zheng  Y , Zhu  J , Liu  Y ,  et al.  Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis.   BMJ. 2018;363:k4388. doi:10.1136/bmj.k4388PubMedGoogle ScholarCrossref
63.
Zhang  L , Huang  G , Jin  L , Han  S .  Therapeutic effects of a long-acting cholinergic receptor blocker, tiotropium bromide, on asthma.   Med Sci Monit. 2018;24:944-950. doi:10.12659/MSM.907950PubMedGoogle ScholarCrossref
64.
Donohue  JF , Wise  R , Busse  WW ,  et al.  Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.   BMC Pulm Med. 2016;16(1):65. doi:10.1186/s12890-016-0223-3PubMedGoogle ScholarCrossref
65.
Griffiths  B , Ducharme  FM .  Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children.   Cochrane Database Syst Rev. 2013;(8):CD000060. doi:10.1002/14651858.CD000060.pub2PubMedGoogle Scholar
66.
Kirkland  SW , Vandenberghe  C , Voaklander  B , Nikel  T , Campbell  S , Rowe  BH .  Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma.   Cochrane Database Syst Rev. 2017;1(1):CD001284. doi:10.1002/14651858.CD001284.pub2PubMedGoogle Scholar
67.
Blais  CM , Davis  BE , Cockcroft  DW .  Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.   Respir Med. 2016;118:96-101. doi:10.1016/j.rmed.2016.07.017PubMedGoogle ScholarCrossref
68.
Yates  DH , Sussman  HS , Shaw  MJ , Barnes  PJ , Chung  KF .  Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment.   Am J Respir Crit Care Med. 1995;152(4 Pt 1):1170-1174. doi:10.1164/ajrccm.152.4.7551366PubMedGoogle ScholarCrossref
69.
Institute for Clinical and Economic Review.  Biologic Therapies for Treatment of Asthma Associated With Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks. November 13, 2018. Accessed December 16, 2020. https://icer.org/wp-content/uploads/2020/10/Asthma-Revised-Report-FOR-PUBLICATION-11.13.2018.pdf
70.
Cloutier  MM , Dixon  AE , Krishnan  JA , Lemanske  RF , Pace  W , Schatz  M .  Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program.  2020;324(22):2301-2317. doi:10.1001/jama.2020.21974PubMed
71.
Sobieraj  DM , Weeda  ER , Nguyen  E ,  et al.  Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis.   JAMA. 2018;319(14):1485-1496. doi:10.1001/jama.2018.2769PubMedGoogle ScholarCrossref
72.
Aziz-Ur-Rehman  A , Dasgupta  A , Kjarsgaard  M , Hargreave  FE , Nair  P .  Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations.   Allergy Asthma Clin Immunol. 2017;13:17. doi:10.1186/s13223-017-0190-0PubMedGoogle ScholarCrossref
73.
Green  RH , Brightling  CE , McKenna  S ,  et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.   Lancet. 2002;360(9347):1715-1721. doi:10.1016/S0140-6736(02)11679-5PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close